Abstract
Nonalcoholic fatty liver disease (NAFLD) currently compromises more than two thirds of patients with chronic liver disease in the United States. The mainstay of treatment of NAFLD is weight loss, which can lead to improvement in hepatic steatosis and fibrosis. The modest effect of life style modification and pharmacotherapy on weight loss is subject to weight recidivism in the majority of patients, and only a small minority of patients ultimately undergo bariatric surgery. Endoscopic sleeve gastroplasty (ESG) can be offered to patients as a component of a comprehensive weight loss program.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
